Business
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern TimeSoligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to
About this update from Soligenix, Inc.
[{"type":"text","content":"Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern TimeSoligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m., Eastern Time on November 16, 2022PRINCETON, N.J., Oct. 20, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the \"Annual Meeting\") has been further adjourned with respect to Proposal 2 (the authorized share increase), as described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the \"SEC\") on August 5, 2022 (the \"Proxy Statement\").\nThe Annual Meeting will reconvene solely with respect to Proposal 2 on November 17, 2022 at 9:00 a.m. Eastern Time and will continue to be held virtually via live audio-only webcast at www.virtualshareholdermeeting.com/sngx2022. \nSupport for Proposal 2 has exceeded 80% of the votes cast on the proposal. However, the affirmative vote of holders of more than 50% of the Company's issued and outstanding shares of common stock is necessary for Proposal 2 to be approved.\nThe record date for determination of stockholders entitled to vote at the reconvened Annual Meeting remains the close of business on July 25, 2022. Any proxies previously submitted with respect to Proposal 2 will continue to be counted, unless properly revoked. Stockholders that have previously voted need not submit a new proxy for their votes to be counted.\nStockholders as of close of business on July 25, 2022, who have not yet voted, are encouraged to vote as soon as possible via the Internet at http://www.proxyvote.com. Stockholders who need assistance voting or have questions may contact the Company's proxy solicitation firm, Alliance Advisors, LLC, at 1-833-782-7145 or [email protected].\nAs the Company moves toward filing a new drug application for HyBryte™ in the fourth quarter, the Company's Board of Directors believes that the approval of Proposal 2 is in the best interest of the Company's stockholders and is critical to continue to operate the business efficiently. The availability of additional authorized shares of common stock is required for seve...